Search results
Results from the WOW.Com Content Network
Insulin detemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes. [6] It is used by injection under the skin. [6] It is effective for up to 24 hours. [6]
Novo Nordisk created insulin detemir and markets it under the trade name Levemir as a long-lasting insulin analogue for maintaining the basal level of insulin. [ 1 ] [ 5 ] The basal level of insulin may be maintained for up to 20 hours, but the time is affected by the size of the injected dose.
Slow-acting insulin such as Lantus or Levemir can be used for a large portion of the basal insulin needs, and the pump basal rate program can be used to fill in the remaining need. Lantus injected once daily is one back-up for pump users, but it can be a real benefit for some insulin pumpers who tend to develop ketoacidosis quickly. [citation ...
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S ...
Disposition index, but not insulin resistance, can predict type 2 diabetes in persons with normal blood glucose levels, but who do not have a family history (genetic predisposition) to type 2 diabetes. [14] Disposition index can be increased by aerobic exercise, but only to the extent that insulin sensitivity is improved. [15]
Basal insulin such as Levemir is a type of long-acting insulin injected once or twice a day as opposed to rapid, short, or intermediate-acting insulin. It is often used by people with Type 1 ...
The hyperglycemic clamps are often used to assess insulin secretion capacity. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained at 100 μU/ml by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion.
The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir but he had to do so because of market forces.